QQQ   325.85 (+0.64%)
AAPL   136.09 (+3.08%)
MSFT   225.28 (+0.42%)
FB   272.59 (+1.91%)
GOOGL   1,905.51 (+1.35%)
AMZN   3,329.60 (+2.03%)
TSLA   849.99 (-0.05%)
NVDA   544.12 (+1.78%)
BABA   260.08 (-2.04%)
CGC   33.50 (-0.39%)
GE   11.20 (-1.67%)
MU   83.41 (-0.11%)
AMD   89.77 (+1.15%)
NIO   57.91 (+0.35%)
T   28.91 (-0.17%)
F   11.83 (+8.93%)
ACB   11.06 (-4.16%)
BA   206.83 (-2.18%)
DIS   172.05 (-0.92%)
NFLX   574.72 (-1.98%)
GILD   67.00 (-1.46%)
QQQ   325.85 (+0.64%)
AAPL   136.09 (+3.08%)
MSFT   225.28 (+0.42%)
FB   272.59 (+1.91%)
GOOGL   1,905.51 (+1.35%)
AMZN   3,329.60 (+2.03%)
TSLA   849.99 (-0.05%)
NVDA   544.12 (+1.78%)
BABA   260.08 (-2.04%)
CGC   33.50 (-0.39%)
GE   11.20 (-1.67%)
MU   83.41 (-0.11%)
AMD   89.77 (+1.15%)
NIO   57.91 (+0.35%)
T   28.91 (-0.17%)
F   11.83 (+8.93%)
ACB   11.06 (-4.16%)
BA   206.83 (-2.18%)
DIS   172.05 (-0.92%)
NFLX   574.72 (-1.98%)
GILD   67.00 (-1.46%)
QQQ   325.85 (+0.64%)
AAPL   136.09 (+3.08%)
MSFT   225.28 (+0.42%)
FB   272.59 (+1.91%)
GOOGL   1,905.51 (+1.35%)
AMZN   3,329.60 (+2.03%)
TSLA   849.99 (-0.05%)
NVDA   544.12 (+1.78%)
BABA   260.08 (-2.04%)
CGC   33.50 (-0.39%)
GE   11.20 (-1.67%)
MU   83.41 (-0.11%)
AMD   89.77 (+1.15%)
NIO   57.91 (+0.35%)
T   28.91 (-0.17%)
F   11.83 (+8.93%)
ACB   11.06 (-4.16%)
BA   206.83 (-2.18%)
DIS   172.05 (-0.92%)
NFLX   574.72 (-1.98%)
GILD   67.00 (-1.46%)
QQQ   325.85 (+0.64%)
AAPL   136.09 (+3.08%)
MSFT   225.28 (+0.42%)
FB   272.59 (+1.91%)
GOOGL   1,905.51 (+1.35%)
AMZN   3,329.60 (+2.03%)
TSLA   849.99 (-0.05%)
NVDA   544.12 (+1.78%)
BABA   260.08 (-2.04%)
CGC   33.50 (-0.39%)
GE   11.20 (-1.67%)
MU   83.41 (-0.11%)
AMD   89.77 (+1.15%)
NIO   57.91 (+0.35%)
T   28.91 (-0.17%)
F   11.83 (+8.93%)
ACB   11.06 (-4.16%)
BA   206.83 (-2.18%)
DIS   172.05 (-0.92%)
NFLX   574.72 (-1.98%)
GILD   67.00 (-1.46%)
Log in
NYSE:TEVA

Teva Pharmaceutical Industries Stock Forecast, Price & News

$11.95
-0.23 (-1.89 %)
(As of 01/21/2021 11:55 AM ET)
Add
Compare
Today's Range
$11.83
Now: $11.95
$12.34
50-Day Range
$9.55
MA: $10.50
$12.55
52-Week Range
$6.25
Now: $11.95
$13.76
Volume144,750 shs
Average Volume12.18 million shs
Market Capitalization$13.05 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.49
Teva Pharmaceutical Industries Limited, a pharmaceutical company, develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, and internationally. The company offers sterile products, hormones, high-potency drugs, and cytotoxic substances in various dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments, and creams. It also develops, manufactures, and sells active pharmaceutical ingredients. In addition, the company provides specialty medicines for use in central nervous system and respiratory indications. Further, its products in the central nervous system and pain area comprise Copaxone for the treatment of relapsing forms of MS; AJOVY for the preventive treatment of migraine; and AUSTEDO for the treatment of tardive dyskinesia and chorea associated with Huntington disease. Additionally, the company's products in the respiratory market include ProAir, ProAir Respiclick, QVAR, Duoresp Spiromax, Braltus, Cinqair/Cinqaero, and AirDuo RespiClick/ArmonAir RespiClick/AirDuo Digihaler for the treatment of asthma and chronic obstructive pulmonary disease, as well as Bendeka, Treanda, Granix, Trisenox, Lonquex, and Tevagrastim/Ratiograstim products in the oncology market. It has collaboration arrangements with Otsuka Pharmaceutical Co. Ltd. and Regeneron Pharmaceuticals, Inc. Teva Pharmaceutical Industries Limited was founded in 1901 and is headquartered in Petach Tikva, Israel.
Teva Pharmaceutical Industries logo

MarketRank

Overall MarketRank

1.39 out of 5 stars

Medical Sector

544th out of 1,926 stocks

Pharmaceutical Preparations Industry

274th out of 773 stocks

Analyst Opinion: 1.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 2.5 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone972-3914-8171
Employees40,039

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$16.89 billion
Cash Flow$4.02 per share
Book Value$13.79 per share

Profitability

Net Income$-998,000,000.00

Miscellaneous

Outstanding Shares1,092,190,000
Market Cap$13.05 billion
Next Earnings Date2/10/2021 (Confirmed)
OptionableOptionable
$11.95
-0.23 (-1.89 %)
(As of 01/21/2021 11:55 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive TEVA News and Ratings via Email

Sign-up to receive the latest news and ratings for TEVA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Teva Pharmaceutical Industries (NYSE:TEVA) Frequently Asked Questions

How has Teva Pharmaceutical Industries' stock price been impacted by COVID-19 (Coronavirus)?

Teva Pharmaceutical Industries' stock was trading at $9.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, TEVA shares have increased by 32.4% and is now trading at $11.93.
View which stocks have been most impacted by COVID-19
.

Is Teva Pharmaceutical Industries a buy right now?

17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last twelve months. There are currently 3 sell ratings, 10 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" Teva Pharmaceutical Industries stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View analyst ratings for Teva Pharmaceutical Industries
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Teva Pharmaceutical Industries?

Wall Street analysts have given Teva Pharmaceutical Industries a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Teva Pharmaceutical Industries wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

What is Thomas Greco's approval rating as Teva Pharmaceutical Industries' CEO?

538 employees have rated Teva Pharmaceutical Industries CEO Thomas Greco on Glassdoor.com. Thomas Greco has an approval rating of 63% among Teva Pharmaceutical Industries' employees. This puts Thomas Greco in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

When is Teva Pharmaceutical Industries' next earnings date?

Teva Pharmaceutical Industries is scheduled to release its next quarterly earnings announcement on Wednesday, February 10th 2021.
View our earnings forecast for Teva Pharmaceutical Industries
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 10th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Thursday, November, 5th. The company reported $0.58 EPS for the quarter, hitting the Zacks' consensus estimate of $0.58. The business earned $4 billion during the quarter, compared to analyst estimates of $4.09 billion. Teva Pharmaceutical Industries had a negative net margin of 24.17% and a positive return on equity of 19.32%. Teva Pharmaceutical Industries's revenue was down 6.2% on a year-over-year basis. During the same period last year, the company earned $0.58 earnings per share.
View Teva Pharmaceutical Industries' earnings history
.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY20 earnings guidance on Thursday, November, 5th. The company provided EPS guidance of $2.40-$2.55 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $2.51. The company issued revenue guidance of $16.5-$16.8 billion, compared to the consensus revenue estimate of $16.69 billion.

What price target have analysts set for TEVA?

17 analysts have issued 1-year price objectives for Teva Pharmaceutical Industries' shares. Their forecasts range from $8.00 to $16.00. On average, they expect Teva Pharmaceutical Industries' stock price to reach $12.29 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price.
View analysts' price targets for Teva Pharmaceutical Industries
or view Wall Street analyst' top-rated stocks.

Who are some of Teva Pharmaceutical Industries' key competitors?

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

Who are Teva Pharmaceutical Industries' key executives?

Teva Pharmaceutical Industries' management team includes the following people:
  • Mr. Kare Schultz, Pres, CEO & Director (Age 60, Pay $5.6M)
  • Mr. Eliyahu Sharon Kalif, Exec. VP & CFO (Age 48, Pay $655.76k)
  • Dr. Hafrun Fridriksdottir, Exec. VP of Global R&D (Age 59, Pay $2.48M)
  • Mr. Brendan P. O'Grady, Exec. VP of North America Commercial (Age 54, Pay $1.56M)
  • Mr. Gianfranco Nazzi, Exec. VP of International Markets Commercial (Age 52, Pay $2.15M)
  • Mr. Eric Drapé, Exec. VP of Global Operations (Age 59)
  • Deborah A. Griffin, Sr. VP & Chief Accounting Officer
  • Mr. Kevin C. Mannix, Sr. VP of Investor Relations
  • Mr. David M. Stark, Exec. VP & Chief Legal Officer (Age 52)
  • Ms. Lori Queisser, Sr. VP & Global Compliance Officer

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by many different retail and institutional investors. Top institutional shareholders include DNB Asset Management AS (0.01%), IFM Investors Pty Ltd (0.01%), Kestra Advisory Services LLC (0.00%), Raymond James Trust N.A. (0.00%), Bellecapital International Ltd. (0.00%) and NuWave Investment Management LLC (0.00%). Company insiders that own Teva Pharmaceutical Industries stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Hafrun Fridriksdottir, Luzich Partners Llc, Mark Sabag, Michael James Mcclellan, Notaristefani Carlo De, Richard Daniell, Rosemary A Crane, Sol J Barer and Sven Dethlefs.
View institutional ownership trends for Teva Pharmaceutical Industries
.

Which institutional investors are selling Teva Pharmaceutical Industries stock?

TEVA stock was sold by a variety of institutional investors in the last quarter, including NuWave Investment Management LLC, Crossmark Global Holdings Inc., Raymond James Trust N.A., Pacer Advisors Inc., and IFM Investors Pty Ltd. Company insiders that have sold Teva Pharmaceutical Industries company stock in the last year include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eric Drape, Mark Sabag, Richard Daniell, and Rosemary A Crane.
View insider buying and selling activity for Teva Pharmaceutical Industries
or view top insider-selling stocks.

Which institutional investors are buying Teva Pharmaceutical Industries stock?

TEVA stock was purchased by a variety of institutional investors in the last quarter, including DNB Asset Management AS, Kestra Advisory Services LLC, and Bellecapital International Ltd..
View insider buying and selling activity for Teva Pharmaceutical Industries
or or view top insider-buying stocks.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $11.93.

How big of a company is Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries has a market capitalization of $13.03 billion and generates $16.89 billion in revenue each year. The company earns $-998,000,000.00 in net income (profit) each year or $2.31 on an earnings per share basis. Teva Pharmaceutical Industries employs 40,039 workers across the globe.

What is Teva Pharmaceutical Industries' official website?

The official website for Teva Pharmaceutical Industries is www.tevapharm.com.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The company can be reached via phone at 972-3914-8171 or via email at [email protected]

This page was last updated on 1/21/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.